Hypertension in older adults

Reviews in Clinical Gerontology

Volumn 14, Issue 3, 2004, Pages 189-198

  Scott, Andrew K ^a  

^a ARROWE PARK HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; ATENOLOL; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LOSARTAN; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT;

AGED; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; COUGHING; DISEASE CONTROL; DRUG RESPONSE; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; ENVIRONMENTAL FACTOR; FOLLOW UP; HEALTH BEHAVIOR; HEALTH CARE COST; HEALTH PROGRAM; HUMAN; HYPERTENSION; MORBIDITY; PATIENT COMPLIANCE; PRACTICE GUIDELINE; REVIEW;

EID: 25844461735     PISSN: 09592598     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0959259805001528     Document Type: Review

References (47)

1. Scott AK. Hypertension in the elderly. Rev Clin Gerontol 1999; 9: 39-54.
2. NHS Centre for Reviews and Dissemination. Drug treatment of essential hypertension in older people. Effect Matters 1999; 4: Issue 2.
3. Starr JM, Inch S, Cross S, MacLennan W, Deary IJ. Blood pressure and ageing: a longitudinal cohort study. BMJ 1998; 317: 513-14.
4. Jackson R. Which elderly patients should be considered for antihypertensive treatment? An evidence-based approach. J Hum Hypertens 1998; 12: 607-13.
5. He FJ, MacGregor GA. Cost of poor blood-pressure control in the UK: 62 000 unnecessary deaths per year. J Hum Hypertens 2003; 17: 455-57.
6. Colhoun HM, Dong W, Poulter NR. Blood-pressure screening, management and control in England: results from the health survey for England 1994. J Hypertens 1998; 16: 747-52.
7. Primatesta P, Poulter NR. Hypertension management and control among English adults aged 65 years and older in 2000 and 2001. J Hypertens 2004; 22: 1093-98.
8. Kearney PM, Whelton M, Reynolds K, Whelton PK, He J. Worldwide prevalence of hypertension: a systematic review. J Hypertens 2004; 22: 11-19.
9. Mancia G, Sega R, Milesi C, Cesana G, Zanchetti A. Blood-pressure control in the hypertensive population. Lancet 1997; 349: 454-57.
10. Duggan S, Eccles MP, Steen N, Jones S, Ford GA. Management of older patients with hypertension in primary care: improvement on the rule of halves. Age Ageing 2001; 30: 73-76.
11. Mallion JM, Genes N, Vaur L et al. Blood pressure levels, risk factors and antihypertensive treatments: lessons from the SHEAF study. J Hum Hypertens 2001; 15: 841-48.
12. Benetos A, Thomas F, Bean KE, Guize L. Why cardiovascular mortality is higher in treated hypertensives versus subjects of the same age, in the general population. J Hypertens 2003; 21: 1635-40.
13. Persson M, Carlberg B, Weinehall L et al. Risk stratification by guidelines compared with risk assessment by risk equations applied to a MONICA sample. J Hypertens 2003; 21: 1089-95.
14. Ramsey LE, Haq IU, Jackson PR, Yeo WW. The Sheffield Table for primary prevention of coronary heart disease corrected. Lancet 1996; 348: 1251-52.
15. Persson M, Carlberg B, Tavelin B, Lindholm LH. Doctors' estimation of cardiovascular risk and willingness to give drug treatment in hypertension: fair risk assessment but defensive treatment policy. J Hypertens 2004; 22: 65-71.
16. Asai Y, Heller R, Kajii E. Hypertension control and medication increase in primary care. J Hum Hypertens J 2002; 16: 313-18.
17. Staessen JA, Thijs L, Fagard R et al. Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial. J Hypertens 2004; 22: 847-57.
18. Brown MJ, Cruickshank JK, Dominiczak AF et al. Better blood-pressure control: how to combine drugs. J Hum Hypertens 2003; 17: 81-86.
19. Birtwhistle RV, Godwin MS, Delva MD et al. Randomised equivalence trial comparing three and six months of follow up of patients with hypertension by family practitioners. BMJ 2004; 328: 204-06.
20. Esposti ED, Sturani A, Martino MD et al. Long-term persistence with antihypertensive drugs in new patients. J Hum Hypertens 2002; 16: 439-44.
21. Hasford J, Mimran A, Simons WR. A population-based European cohort study of persistence in newly diagnosed hypertensive patients. J Hum Hypertens 2002; 16: 569-75.
22. UK Prospective Diabetes Study Group. Cost-effectiveness analysis of improved blood-pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. BMJ 1998; 317: 720-26.
23. Staessen JA, Wang J-G, Thijs L. Cardiovascular prevention and blood-pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens 2003; 21: 1055-76.
24. Marshall T. When measurements are misleading: modelling the effects of blood-pressure misclassification in the English population. BMJ 2004; 328: 933.
25. O'Brien E, Asmar R, BeilinL et al. European Society of Hypertension recommendations for conventional, ambulatory and home blood-pressure measurement. J Hypertens 2003; 21: 821-48.
26. O'Brien E, Coats A, Owens P et al. Use and interpretation of ambulatory blood pressure monitoring: recommendations of the British Hypertension Society. BMJ 2000; 320: 1128-1134.
27. Staessen JA, Thijs L, Fagard R et al. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. JAMA 1999; 282: 539-46.
28. O'Sullivan C, Duggan J, Atkins N, O'Brien E. Twenty-four hour ambulatory blood pressure in community dwelling elderly men and women, aged 60-102 years. J Hypertens 2003; 21: 1641-47.
29. van der Steen MS, Lenders JWM, Graafsma SJ, den Arend J, Thien T. Reproducibility of ambulatory blood pressure monitoring in daily practice. J Hum Hypertens 1999; 13: 303-08.
30. Rickerby J. The role of home blood-pressure measurement in managing hypertension: an evidence-based review. J Hum Hypertens 2002; 16: 469-72.
31. Mancia G, Parati G. Office compared with ambulatory blood pressure in assessing response to antihypertensive treatment: a meta-analysis. J Hypertens 2004; 22: 435-45.
32. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel-blocker vs. diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-97.
33. The ASCOT investigators. Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. J Hypertens 2001; 19: 1139-47.
34. Dahlof B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint Reduction in Hypertension Study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.
35. Kjeldsen LE, Dahlof B, Devereux RB et al. Effects of Losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy. A Losartan Intervention For Endpoint reduction (LIFE) substudy. JAMA 2002; 288: 1491-1498.
36. Lithell H, Hansson L, Skoog I et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21: 875-886.
37. Lindholm LH, Hansson L, Ekbom T et al. for the STOP Hypertension-2 Study Group. Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish Trial in Old Patients with Hypertension - 2. J Hypertens 2000; 18: 1671-1675.
38. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317: 713-20.
39. UK Prospective Diabetes Study Group. Tight blood-pressure control and risk of macrovascular and microvascular complications in type 2 diabetes:UKPDS 38. BMJ 1998; 317: 703-13.
40. Bulpitt CJ, Beckett NS, Cooke J et al. on behalf of the Hypertension in the Very Elderly Trial (HYVET) Working Group. Results of the pilot study for the Hypertension in the Very Elderly Trial. J Hypertens 2003; 21: 2409-17.
41. Scottish Intercollegiate Guidelines Network. Hypertension in Older People. SIGN Publications 2001, 49.
42. Williams B, Poulter NR, Brown MJ et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society (2004-BHS IV) J Hum Hypertens 2004; 18: 139-85.
43. Guidelines Committee. 2003 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-53.
44. World Health Organisation, International Society of Hypertension Writing Group, 2003 World Health Organisation (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21: 1983-92.
45. MRC Working Party 1992. Medical Research Council trial of treatment of mild hypertension, principal results. BMJ 1992; 291: 97-104.
46. Stanton T, Reid JL. Fixed-dose combination therapy in the treatment of hypertension. J Hum Hypertens 2002; 16: 75-78.
47. Girvin B, Johnston GD. A randomized comparison of a conventional dose, a low dose and alternate-day dosing of bendrofluazide in hypertensive patients. J Hypertens 1998; 16: 1049-54.